Temozolomide NEW
| Price | $42 | $68 | $82 |
| Package | 10mg | 25mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-15 |
Product Details
| Product Name: Temozolomide | CAS No.: 85622-93-1 |
| Purity: 99.87% | Supply Ability: 10g |
| Release date: 2024/11/15 |
Product Introduction
Bioactivity
| 名稱 | Temozolomide |
| 描述 | Temozolomide (TMZ) is a DNA alkylating agent with blood-brain barrier permeability and oral activity. Temozolomide has antitumor activity and antiangiogenic activity, and also induces apoptosis and autophagy. Temozolomide is stable under acidic conditions and hydrolyzes under neutral or slightly alkaline conditions. |
| 細胞實驗 | Cell lines exposed to TMZ (with or without 5-Aza or O6-BG pre-treatment) were grown in 24-well plates under standard culture conditions for 6 days. Cytotoxicity was determined using the sulphorhodamine-B (SRB) method. Briefly, the cells were fixed with 10% trichloroacetic acid for 20 min at 4°C then washed three times with water. After 24 hours, cells were stained for 30 min at room temperature with 0.4% SRB dissolved in 1% acetic acid and then washed three times with 1% acetic acid. The plates were air-dried and the dye solubilized with 300 ml/well of 10 mM Tris base (pH 10.5) for 10 min on a shaker. The optical density of each well was measured spectrophotometrically using a Titertek multiscan colorimeter at 492 nm [2]. |
| 動物實驗 | TZM was dissolved in dimethyl-sulfoxide (40 mg/mL), diluted in saline (5 mg/mL), and administered intraperitoneally on day 2 after tumor injection at 100 mg/kg or 200 mg/kg, doses commonly used for in vivo preclinical studies.15-17 Because cytotoxicity induced by TZM and PARP inhibitors can be improved by fractionated modality of treatment,9 in selected groups a total dose of 200 mg/kg TZM was divided in 2 doses of 100 mg/kg given on days 2 and 3. NU1025 was dissolved in polyethylene glycol-400 (40% in saline) and was injected intracranially at the maximal deliverable dose (1 mg/mouse, 0.03 mL) or, in selected groups, intraperitoneally (0.3 mL) on day 2 after tumor challenge, 1 hour before TZM administration. Control mice were injected with drug vehicles [4]. |
| 體外活性 | METHODS: Melanoma cells SK-mel-28, MM200, IgR3, Mel-FH were treated with Temozolomide (0-500 μM) for 72 h. Cell viability was examined using MTT. RESULTS: The p53 status and MGMT expression levels were correlated with the sensitivity of Temozolomide. MM200 and IgR3 (expressing wild-type p53 and low MGMT levels) showed comparable sensitivity to Temozolomide, with IC50 values of 23 and 22 μM, respectively, whereas SK mel-28 and Mel-FH (mutant-type p53 and high MGMT level) were resistant with IC50 values >256 and >247 μM. [1] METHODS: Melanoma cells MM200 and IgR3 were treated with Temozolomide (100 μM) for 24-72 h. The cell cycle was examined by Flow Cytometry. RESULTS: Temozolomide induced G2/M cell cycle arrest in MM200 and IgR3 cells. [1] METHODS: Human glioma cells U118 were treated with Temozolomide (250-500 μM) for 3-48 h. The m5C level in DNA was measured. RESULTS: The response of U118 cells to Temozolomide depends on the concentration and time of the reaction. The amount of m5C in DNA increased significantly within a short period of time after Temozolomide treatment. m5C(R) reached the highest level after 24 h of treatment with 500 μM Temozolomide. [2] |
| 體內活性 | METHODS: To assay antitumor activity in vivo, Temozolomide (68 mg/kg by gavage) and AG-014699 (1 mg/kg by intraperitoneal injection) were administered intraperitoneally to CD1 nu/nu mice harboring medulloblastomas D425Med, D283Med, or D384Med once daily for five days. RESULTS: AG-014699 enhanced the efficacy of Temozolomide in an in vivo model of medulloblastoma. [3] METHODS: To assay antitumor activity in vivo, Temozolomide (0.9 mg/kg orally once daily) and Aldox (16 mg/kg intravenously once weekly) were administered to Foxn1 nude mice bearing human glioblastoma U87MG once daily for five weeks. RESULTS: Combined treatment with Temozolomide and AldoxAldo induced significant tumor volume suppression and increased survival. [4] |
| 存儲條件 | store under nitrogen,keep away from direct sunlight | Powder: -20°C for 3 years | Shipping with blue ice. |
| 溶解度 | PBS : 5 mg/mL (25.75 mM), Sonication is recommended.(The compound is unstable in PBS. Please use soon) DMSO : 28.83 mg/mL (200 mM) 10% DMSO+90% Saline : 2.88 mg/mL (14.83 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. |
| 關鍵字 | DNA Alkylator/Crosslinker | Inhibitor | Apoptosis | Temozolomide | inhibit | CCRG-81045 | NSC362856 | NSC-362856 | Autophagy | CCRG81045 |
| 相關產品 | Stavudine | Sodium 4-phenylbutyrate | L-Ascorbic acid | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Tributyrin | Paeonol | Thymidine | Naringin | Salicylic acid | Gefitinib |
| 相關庫 | 抗癌天然產物庫 | 經典已知活性庫 | 中藥單體化合物庫 | EMA 上市藥物庫 | 抗癌臨床化合物庫 | 天然產物庫 | 藥物功能重定位化合物庫 | 高通量篩選天然產物庫 | 抗癌上市藥物庫 | FDA 上市藥物庫 | 抗衰老化合物庫 | 抗癌活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $42.00/10mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-15 | |
| $10.00/1kg |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-20 | |
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-08-09 | |
| $40.00/10mg |
VIP2Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2024-07-10 | |
| $5.00/25kg |
Ouhuang Engineering Materials (Hubei) Co., Ltd
|
2024-04-28 | ||
| $32.00/1KG |
VIP1Y
|
Henan Fengda Chemical Co., Ltd
|
2024-04-15 | |
| $50.00/1kg |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-09-22 | |
| $0.00/25KG |
VIP5Y
|
Hebei Mojin Biotechnology Co., Ltd
|
2022-07-12 | |
| $15.00/1kg |
Hebei Linwo New Material Technology Co., LTD
|
2022-06-27 | ||
| $10.00/1kg |
Jiangsu Bangdeya New Material Technology Co.,Ltd
|
2022-04-22 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY